


Supplemental Figure Legend

Supplemental Figure 1. Percent change in sCD14, oxLDL, and Lp-PLA2 at Week 52 in Pitavastatin group compared to Pravastatin group (Per Protocol Population). At Week 52, the pitavastatin group had a significantly greater reduction (% change) in sCD14, oxLDL, and Lp-PLA2 (sCD14: -10.0 vs. 0.6%, $P=0.02$; oxLDL -27.5 vs. -17.2%, $P=0.01$; Lp-PLA2 -25.0 vs. -16.4%, $P=0.01$). Data are median (IQR). P-values shown are for between group difference in percent change at Week 52.

Abbreviations: sCD14, soluble CD14; oxLDL, oxidized low density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2

* $P<0.05$ for within group difference



Supplemental Table 1. Correlation Analysis for Percent Change at Week 52 and Percent Change in LDL-C at Week 52 (mITT population)

	Percent Change LDL-C All Subjects	Percent Change LDL-C Pitavastatin	Percent Change LDL-C Pravastatin
Percent Change sCD163	$\rho = 0.09$ P= 0.20	$\rho = -0.01$ P= 0.90	$\rho = 0.23$ P=0.03
Percent Change hsIL-6	$\rho = -0.09$ P=0.22	$\rho = -0.08$ P=0.47	$\rho = -0.09$ P=0.41
Percent Change MCP-1	$\rho = -0.005$ P=0.94	$\rho = -0.06$ P=0.59	$\rho = 0.08$ P=0.42
Percent Change sCD14	$\rho = 0.04$ P=0.63	$\rho = -0.04$ P=0.69	$\rho = -0.003$ P=0.98
Percent Change oxLDL	$\rho = 0.59$ P<0.0001	$\rho = 0.55$ P<0.0001	$\rho = 0.52$ P<0.0001
Percent Change Lp-PLA2	$\rho = 0.64$ P<0.0001	$\rho = 0.56$ P<0.0001	$\rho = 0.66$ P<0.0001

Supplemental Table 1. Significant P-values are shown in bold. Data are shown for mITT population with biomarker specimens available for Week 52.

Abbreviations: LDL-C, low density lipoprotein cholesterol; sCD163, soluble CD163; hsIL-6, high sensitivity interleukin-6; MCP-1, monocyte chemoattractant protein-1; sCD14, soluble CD14; oxLDL, oxidized low density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A

Supplemental Table 2. Markers of Immune Activation and Arterial Inflammation at Baseline and Percent Change at Week 52 Stratified by Sex (mITT population)

	Baseline Females	Baseline Males	P-value	Percent Change Week 52 Females Pitavastatin	Percent Change Week 52 Females Pravastatin	P-value	Percent Change Week 52 Males Pitavastatin	Percent Change Week 52 Males Pravastatin	P-value
sCD163 (ng/mL)	1098 (927, 1499) N=30	943 (722, 1245) N=199	0.01	11.5 (-8.1, 19.7) N=14	6.9 (-10.3, 29.2) N=12	0.78	-1.6 (-12.6, 16.3) N=84	-3.2 (-14.8, 15.5) N=86	0.81
hsIL-6 (pg/mL)	1.1 (0.9, 1.8) N= 30	1.0 (0.7, 1.5) N= 199	0.12	6.1 (-26.0, 71.8) N=14	26.5 (-15.4, 68.5) N=12	0.78	0.8 (-29.4, 34.5) N=84	7.6 (-24.1, 39.0) N=86	0.46
MCP-1 (pg/ml)	136.8 (107.4, 206.1) N=29	142.6 (110.1, 183.0) N=198	0.79	10.1 (-6.8, 24.0) N=14	-22.9 (-39.7, 34.1) N=11	0.22	-2.8 (-22.8, 18.1) N=82	1.3 (-14.2, 18.4) N=84	0.57
sCD14 (ng/mL)	1,847 (1,487, 2,091) N=30	1,735 (1,352, 2,130) N=199	0.48	-24.3 (-47.7, 0.2) N=14	17.8 (1.4, 39.4) N=12	0.004	-6.0 (-19.7, 12.5) N=84	-2.0 (-16.2, 16.3) N=86	0.20
oxLDL (U/L)	77.7 (58.6, 86.0) N=30	77.3 (63.1, 90.4) N=198	0.34	-33.3 (-39.5, -26.5) N=14	-13.2 (-30.8, -4.4) N=12	0.04	-26.2 (-35.1, -9.8) N=83	-17.6 (-29.4, -4.5) N=83	0.09
Lp-PLA2 (ng/mL)	154 (128, 184) N=30	194 (155, 236) N=199	0.0002	-28.2 (-38.9, 6.9) N=14	-10.6 (-27.4, 24.5) N=12	0.27	-26.6 (-34.7, -9.2) N=83	-15.8 (-28.1, -3.6) N=84	0.009

Supplemental Table 2. Data are shown as median (interquartile range); Significant between group P-values are shown in bold.

Abbreviations: sCD163, soluble CD163; hsIL-6, high sensitivity interleukin-6; MCP-1, monocyte chemoattractant protein-1; sCD14, soluble CD14; oxLDL, oxidized low density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2.

Supplemental Table 3. Normally distributed data are reported as mean $\pm$ standard deviation and non-normally distributed data are reported as median (interquartile range), except for cardiac biomarkers which are all presented as median (interquartile range).

* Baseline numbers represent participants who have a paired Baseline sample and Week 12 biomarker samples or a paired Baseline sample and Week 52 biomarker samples

No differences between baseline values unless indicated, ** P-value=0.01

Abbreviations: eGFR, estimated glomerular filtration rate; TSH, thyroid stimulating hormone; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; BMI, body mass index; HIV-1, Human Immunodeficiency Virus-1; sCD163, soluble CD163; hsIL-6, high sensitivity interleukin-6; MCP-1, monocyte chemoattractant protein-1; sCD14, soluble CD14; oxLDL, oxidized low density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2

	Pitavastatin	Pravastatin
Age	50 (46, 56) N=94	50 (45, 56) N=90
Sex, % Male	88% (83/94)	88% (79/90)
Race		
White	85% (80/94)	80% (72/90)
Black	13% (12/94)	16% (14/90)
Asian	1% (1/94)	0% (0/90)
Other	1% (1/94)	4% (4/90)
Hispanic	20% (19/94)	28% (25/90)
Hepatitis B/C	7% (7/94)	11% (10/90)
eGFR (ml/min/1.73m ²)	78 (70, 89) N=94	79 (71, 89) N=90
TSH (mIU/L)	1.6 (1.2, 2.3) N=94	1.6 (1.0, 2.1) N=90
Total Cholesterol (mg/dL)	235 (219, 262) N=94	235 (221, 259) N=90
HDL-C (mg/dL)	47 (39, 55) N=94	47 (41, 57) N=90
LDL-C (mg/dL)	155 (137, 173) N=89	151 (135, 171) N=89
Triglycerides (mg/dL)	149 (110, 221) N=94	153 (115, 216) N=90
BMI (kg/m ²)	27 (25, 30) N=94	28 (24, 31) N=90
Framingham Risk Score (%)	6 (3, 10) N=94	5 (3, 8) N=90
Log HIV-1 Viral Load (copies/ml)	1.1 ± 0.2 N=93	1.1 ± 0.2 N=88
CD4 count (cells/mm ³)**	682 (460, 876) N=93	561 (437, 765) N=90
sCD163 (ng/mL)	980 (704, 1,332) N=93	937 (731, 1,141) N=90
hsIL-6 (pg/mL)	0.9 (0.7, 1.3) N=93	1.1 (0.7, 1.6) N=90
MCP-1 (pg/ml)	141.5 (108.0, 190.6) N=93	134.3 (106.5, 178.5) N=88
sCD14 (ng/mL)	1,792 (1,349, 2,255) N=93	1,760 (1,427, 2,081) N=90
oxLDL (U/L)	78.9 (62.3, 94.3) N=93	78.0 (65.2, 89.3) N=89
Lp-PLA-2 (ng/mL)	194 (157, 224) N=93	178 (135, 245) N=90

Supplemental Table 4. Change in Markers of Immune Activation and Arterial Inflammation at Week 12 (Per Protocol Population)

	Change in Pitavastatin	Change in Pravastatin	P-value*	Percent Change in Pitavastatin	Percent Change in Pravastatin	P-value*
sCD163 (ng/mL)	-40.5 (-135.6, 112.0) N=93	-21.1 (-117.7, 100.4) N=89	0.90	-4.5 (-15.2, 11.7) N=93	-2.0 (-13.3, 10.7) N=89	0.81
hsIL-6 (pg/mL)	0.0 (-0.3, 0.2) N=93	0.0 (-0.4, 0.1) N=89	0.43	-4.3 (-27.9, 28.1) N=93	-3.2 (-32.8, 18.2) N=89	0.42
MCP-1 (pg/ml)	-8.9 (-39.5, 14.0)** N=91	-1.0 (-29.9, 21.8) N=87	0.34	-5.6 (-19.7, 10.1) N=91	-1.1 (-18.6, 18.4) N=87	0.29
sCD14 (ng/mL)	-25.4 (-347.4, 209.0) N=93	-82.6 (-242.6, 102.8) N=89	0.83	-1.4 (-17.3, 13.1) N=93	-3.9 (-13.6, 7.0) N=89	0.65
oxLDL (U/L)	-18.3 (-30.4, -11.0)** N=93	-14.4 (-24.0, -6.0)** N=88	0.008	-26.7 (-35.4, - 16.4) N=93	-20.4 (-29.4, -8.7) N=88	0.004
Lp-PLA2 (ng/mL)	-45.2 (-71.7, -22.2)** N=93	-31.4 (-53.3, -11.6)** N=89	0.02	-23.3 (-36.5, - 13.1) N=93	-18.1 (-30.5, -7.7) N=89	0.03

Supplemental Table 4. Data are shown as median (interquartile range); Significant between group P-values are shown in bold.

* P-value for between group difference

**P<0.05 for within group difference

Abbreviations: sCD163, soluble CD163; hsIL-6, high sensitivity interleukin-6, MCP-1, monocyte chemoattractant protein-1; sCD14, soluble CD14; oxLDL, oxidized low density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2

Supplemental Table 5. Change in Markers of Immune Activation and Arterial Inflammation at Week 52 (Per Protocol

Population)

	Change in Pitavastatin	Change in Pravastatin	P-value*	Percent Change in Pitavastatin	Percent Change in Pravastatin	P-value*
sCD163 (ng/mL)	-1.3 (-142.3, 105.3) N=90	-29.6 (-129.3, 121.4) N=88	0.85	-0.5 (-12.7, 15.2) N=90	-2.7 (-14.5, 15.6) N=88	0.90
hsIL-6 (pg/mL)	0.0 (-0.3, 0.3) N=90	0.1 (-0.3, 0.4) N=88	0.53	1.3 (-28.2, 33.1) N=90	7.9 (-23.2, 43.3) N=88	0.34
MCP-1 (pg/ml)	-2.4 (-33.0, 25.7) N=88	2.6 (-21.0, 27.3) N=85	0.45	-1.7 (-22.7, 20.3) N=88	1.8 (-15.7, 23.0) N=85	0.50
sCD14 (ng/mL)	-156.4 (-476.3, 105.7)** N=90	10.7 (-310.8, 308.6) N=88	0.02	-10.0 (-21.0, 8.7) N=90	0.6 (-15.2, 20.8) N=88	0.02
oxLDL (U/L)	-21.1 (-33.9, -8.3)** N=89	-12.4 (-24.5, -3.8)** N=85	0.01	-27.5 (-36.8, -10.1) N=89	-17.2 (-30.6, -4.5) N=85	0.01
Lp-PLA2 (ng/mL)	-43.3 (-78.5, -11.2)** N=89	-29.6 (-52.4, -6.2)** N=86	0.03	-25.0 (-36.0, -9.2) N=89	-16.4 (-28.3, -4.9) N=86	0.01

Supplemental Table 5. Data are shown as median (interquartile range); Significant between group P-values are shown in bold.

* P-value for between group difference

**P<0.05 for within group difference

Abbreviations: sCD163, soluble CD163; hsIL-6, high sensitivity interleukin-6; MCP-1, monocyte chemoattractant protein-1; sCD14, soluble CD14; oxLDL, oxidized low density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2

Supplemental Table 6. Correlation Analysis for Percent Change at Week 52 and Baseline Demographics (Per Protocol Population)

	Percent Change sCD14	Percent Change oxLDL	Percent Change Lp- PLA2
Age	$\rho = -0.04$ P=0.63	$\rho = -0.02$ P=0.84	$\rho = -0.08$ P=0.29
Framingham Risk Score	$\rho = -0.09$ P=0.23	$\rho = 0.10$ P=0.18	$\rho = 0.00$ P=1.00
CD4 count	$\rho = 0.11$ P=0.15	$\rho = 0.00$ P=0.97	$\rho = 0.02$ P=0.84
Log HIV-1 Viral Load	$\rho = 0.07$ P=0.37	$\rho = 0.06$ P=0.40	$\rho = 0.13$ P=0.08
LDL-C	$\rho = 0.03$ P=0.74	$\rho = -0.17$ P=0.03	$\rho = -0.26$ P=0.0007
sCD14	$\rho = -0.51$ P <0.0001	$\rho = -0.03$ P=0.68	$\rho = 0.005$ P=0.95
oxLDL	$\rho = -0.05$ P=0.54	$\rho = -0.33$ P <0.0001	$\rho = -0.02$ P=0.76
Lp-PLA2	$\rho = -0.07$ P=0.36	$\rho = 0.03$ P=0.65	$\rho = -0.27$ P=0.0003

Supplemental Table 6. Significant P-values are shown in bold. Abbreviations: LDL-C, low density lipoprotein cholesterol; sCD14, soluble CD14; oxLDL, oxidized low density lipoprotein, Lp-PLA2; lipoprotein-associated phospholipase A2

Supplemental Table 7. Correlation Analysis for Percent Change at Week 52 and Percent Change in LDL-C at Week 52 (Per Protocol Population)

	Percent Change LDL-C All Subjects	Percent Change LDL- C Pitavastatin	Percent Change LDL- C Pravastatin
Percent Change sCD163	$\rho = 0.05$ P= 0.56	$\rho = -0.08$ P= 0.46	$\rho = 0.17$ P= 0.11
Percent Change hsIL-6	$\rho = -0.11$ P=0.16	$\rho = -0.12$ P= 0.30	$\rho = -0.08$ P=0.49
Percent Change MCP-1	$\rho = 0.01$ P=0.87	$\rho = -0.07$ P= 0.54	$\rho = 0.10$ P=0.35
Percent Change sCD14	$\rho = 0.05$ P=0.50	$\rho = -0.03$ P= 0.81	$\rho = 0.02$ P= 0.82
Percent Change oxLDL	$\rho = 0.58$ P<0.0001	$\rho = 0.54$ P<0.0001	$\rho = 0.47$ P<0.0001
Percent Change Lp- PLA2	$\rho = 0.65$ P<0.0001	$\rho = 0.58$ P<0.0001	$\rho = 0.66$ P<0.0001

Supplemental Table 7. Significant P-values are shown in bold. Data are shown for PPP with biomarker specimens available for Week 52.

Abbreviations: LDL-C, low density lipoprotein cholesterol; sCD163, soluble CD163; hsIL-6, high sensitivity interleukin-6; MCP-1, monocyte chemoattractant protein-1; sCD14, soluble CD14; oxLDL, oxidized low density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A

Supplemental Table 8. Markers of Immune Activation and Arterial Inflammation at Baseline and Percent Change at Week 52 Stratified by Sex (Per Protocol Population)

	Baseline Females	Baseline Males	P-value	Percent Change Week 52 Females Pitavastatin	Percent Change Week 52 Females Pravastatin	P-value	Percent Change Week 52 Males Pitavastatin	Percent Change Week 52 Males Pravastatin	P-value
sCD163 (ng/mL)	1085 (808, 1470) N=22	939 (705, 1215) N=161	0.12	11.1 (-10.9, 19.5) N=11	4.6 (-10.3, 31.6) N=11	1.00	-1.9 (-13.0, 13.9) N=79	-3.4 (-14.9, 14.9) N=77	0.87
hsIL-6 (pg/mL)	1.0 (0.8, 1.8) N=22	1.0 (0.7, 1.5) N=161	0.21	4.2 (-28.1, 68.2) N=11	28.3 (-18.9, 70.7) N=11	0.51	0.8 (-28.5, 32.4) N=79	7.8 (-24.6, 40.0) N=77	0.46
MCP-1 (pg/ml)	135.5 (105.6, 187.4) N=21	140.5 (107.7, 184.1) N=160	0.76	11.4 (-6.3, 25.4) N=11	-16.2 (-40.9, 47.0) N=10	0.34	-3.8 (-23.7, 13.0) N=77	2.5 (-13.3, 21.8) N=75	0.19
sCD14 (ng/mL)	1839 (1274, 2066) N=22	1761 (1382, 2152) N=161	0.84	-17.1 (-58.5, -1.2) N=11	18.7 (0.6, 41.9) N=11	0.003	-6.1 (-18.9, 9.1) N=79	-1.7 (-16.4, 18.0) N=77	0.19
oxLDL (U/L)	77.7 (60.0, 82.1) N=22	78.2 (64.3, 93.1) N=160	0.17	-36.3 (-42.9, -29.6) N=11	-13.2 (-31.1, -3.1) N=11	0.04	-26.4 (-35.3, -9.6) N=78	-17.2 (-29.4, -4.5) N=74	0.06
Lp-PLA2 (ng/mL)	153 (128, 170) N=22	194 (157, 235) N=161	0.0005	-25.0 (-38.7, 7.1) N=11	-14.3 (-29.2, 30.9) N=11	0.43	-25.5 (-35.2, -9.5) N=78	-16.9 (-28.2, -5.7) N=75	0.01

Supplemental Table 8. Data are shown as median (interquartile range); Significant between group P-values are shown in bold.

Abbreviations: sCD163, soluble CD163; hsIL-6, high sensitivity interleukin-6; MCP-1, monocyte chemoattractant protein-1; sCD14, soluble CD14; oxLDL, oxidized low density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2